Telix Ebit vs Interest Income Analysis

TLX Stock   24.62  0.12  0.49%   
Telix Pharmaceuticals financial indicator trend analysis is much more than just breaking down Telix Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Telix Pharmaceuticals is a good investment. Please check the relationship between Telix Pharmaceuticals Ebit and its Interest Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Ebit vs Interest Income

Ebit vs Interest Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Telix Pharmaceuticals Ebit account and Interest Income. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Telix Pharmaceuticals' Ebit and Interest Income is -0.06. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Interest Income in the same time period over historical financial statements of Telix Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Telix Pharmaceuticals' Ebit and Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Telix Pharmaceuticals are associated (or correlated) with its Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Income has no effect on the direction of Ebit i.e., Telix Pharmaceuticals' Ebit and Interest Income go up and down completely randomly.

Correlation Coefficient

-0.06
Relationship DirectionNegative 
Relationship StrengthInsignificant

Ebit

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.
Most indicators from Telix Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Selling General Administrative is likely to gain to about 82.9 M in 2024, despite the fact that Tax Provision is likely to grow to (2 M).

Telix Pharmaceuticals fundamental ratios Correlations

0.740.660.530.61-0.62-0.840.720.680.760.680.740.920.930.770.620.690.770.650.640.86-0.7-0.240.640.940.61
0.740.980.90.96-0.84-0.910.980.730.980.730.990.880.790.980.960.980.990.980.980.92-0.390.170.940.750.97
0.660.980.850.99-0.77-0.910.990.650.970.650.990.820.750.980.990.960.981.01.00.9-0.410.170.960.691.0
0.530.90.850.81-0.87-0.660.830.740.840.740.840.680.520.790.810.920.830.870.850.67-0.030.340.830.540.85
0.610.960.990.81-0.74-0.910.970.630.950.630.980.790.750.971.00.940.960.990.990.88-0.360.190.950.670.98
-0.62-0.84-0.77-0.87-0.740.74-0.73-0.93-0.72-0.93-0.76-0.71-0.65-0.77-0.74-0.92-0.84-0.8-0.79-0.70.03-0.34-0.8-0.55-0.76
-0.84-0.91-0.91-0.66-0.910.74-0.92-0.69-0.91-0.69-0.94-0.92-0.93-0.97-0.91-0.89-0.96-0.9-0.9-0.970.60.02-0.89-0.84-0.88
0.720.980.990.830.97-0.73-0.920.610.980.611.00.870.780.980.980.940.970.980.980.92-0.490.050.930.750.98
0.680.730.650.740.63-0.93-0.690.610.611.00.650.640.70.670.630.80.740.680.670.63-0.010.290.70.550.63
0.760.980.970.840.95-0.72-0.910.980.610.610.980.90.810.980.950.920.960.960.950.94-0.520.080.90.810.94
0.680.730.650.740.63-0.93-0.690.611.00.610.650.640.70.670.630.80.740.680.670.63-0.010.290.70.550.63
0.740.990.990.840.98-0.76-0.941.00.650.980.650.880.80.990.980.960.990.990.980.93-0.470.090.950.770.98
0.920.880.820.680.79-0.71-0.920.870.640.90.640.880.920.910.790.830.90.80.80.97-0.69-0.170.740.910.78
0.930.790.750.520.75-0.65-0.930.780.70.810.70.80.920.860.750.750.840.730.730.94-0.67-0.10.720.910.7
0.770.980.980.790.97-0.77-0.970.980.670.980.670.990.910.860.970.950.990.970.970.97-0.530.090.930.80.96
0.620.960.990.811.0-0.74-0.910.980.630.950.630.980.790.750.970.940.960.990.990.89-0.380.180.950.670.99
0.690.980.960.920.94-0.92-0.890.940.80.920.80.960.830.750.950.940.980.970.970.87-0.270.250.950.680.95
0.770.990.980.830.96-0.84-0.960.970.740.960.740.990.90.840.990.960.980.980.970.95-0.450.110.950.790.96
0.650.981.00.870.99-0.8-0.90.980.680.960.680.990.80.730.970.990.970.981.00.88-0.350.20.970.690.99
0.640.981.00.850.99-0.79-0.90.980.670.950.670.980.80.730.970.990.970.971.00.88-0.360.20.960.661.0
0.860.920.90.670.88-0.7-0.970.920.630.940.630.930.970.940.970.890.870.950.880.88-0.68-0.050.840.890.86
-0.7-0.39-0.41-0.03-0.360.030.6-0.49-0.01-0.52-0.01-0.47-0.69-0.67-0.53-0.38-0.27-0.45-0.35-0.36-0.680.5-0.3-0.69-0.36
-0.240.170.170.340.19-0.340.020.050.290.080.290.09-0.17-0.10.090.180.250.110.20.2-0.050.50.31-0.240.2
0.640.940.960.830.95-0.8-0.890.930.70.90.70.950.740.720.930.950.950.950.970.960.84-0.30.310.680.95
0.940.750.690.540.67-0.55-0.840.750.550.810.550.770.910.910.80.670.680.790.690.660.89-0.69-0.240.680.63
0.610.971.00.850.98-0.76-0.880.980.630.940.630.980.780.70.960.990.950.960.991.00.86-0.360.20.950.63
Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Telix Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding233.4M257.3M282.2M310.6M323.7M221.8M
Total Assets102.6M164.4M109.8M260.6M398.3M418.2M
Total Current Liabilities10.6M20.0M38.0M85.6M157.4M165.3M
Total Stockholder Equity70.1M79.0M2.2M80.0M148.9M156.4M
Property Plant And Equipment Net1.9M4.8M6.3M18.8M30.5M32.0M
Net Debt(42.5M)(75.7M)(19.5M)(105.9M)(105.8M)(100.5M)
Retained Earnings(48.1M)(93.0M)(173.5M)(272.8M)(263.7M)(250.5M)
Accounts Payable7.0M5.8M11.9M16.8M32.8M34.5M
Cash44.6M77.9M22.0M116.3M123.2M63.5M
Non Current Assets Total43.9M70.8M62.3M87.4M173.5M182.1M
Cash And Short Term Investments44.6M77.9M22.0M116.3M123.2M63.5M
Net Receivables13.0M14.2M20.8M39.4M64.8M68.0M
Liabilities And Stockholders Equity102.6M164.4M109.8M260.6M398.3M418.2M
Non Current Liabilities Total21.3M64.5M68.2M92.9M92.0M48.8M
Total Liab31.9M84.4M106.2M178.4M249.4M261.9M
Property Plant And Equipment Gross1.9M4.8M8.4M22.2M36.3M38.1M
Total Current Assets58.7M93.6M47.5M173.2M224.8M236.1M
Common Stock115.9M167.1M170.8M371.0M446.3M468.6M
Short Long Term Debt Total2.1M2.2M2.5M10.4M17.4M18.3M
Other Current Liab3.2M10.1M19.3M55.8M100.5M105.5M
Other Liab20.3M57.4M67.8M80.0M92.0M96.6M
Net Tangible Assets28.1M19.8M(53.6M)21.0M18.9M10.2M
Non Currrent Assets Other(4.1M)183K(3.9M)327K586K615.3K
Other Assets82K183K212K4.0M4.6M4.8M
Long Term Debt Total1.6M1.4M1.9M9.8M11.3M11.8M
Inventory542K633K3.5M8.5M17.3M18.2M
Other Current Assets530K859K1.2M9.1M19.5M20.5M
Other Stockholder Equity2.2M4.9M4.8M(562K)(1.0)(0.95)
Net Invested Capital70.8M79.4M2.2M83.3M158.1M166.0M
Short Long Term Debt469K264K19K964K867.6K911.0K
Accumulated Other Comprehensive Income2.2M4.9M4.8M(18.2M)(33.7M)(32.0M)
Net Working Capital48.1M73.7M9.6M87.7M67.4M56.9M
Short Term Debt490K767K632K641K1.6M874.9K
Intangible Assets41.9M59.2M55.7M59.0M104.8M56.3M
Property Plant Equipment1.9M4.8M6.3M18.8M21.7M22.7M
Long Term Debt292K95K0.03.3M8.2M8.6M
Capital Stock115.9M167.1M170.8M371.0M446.3M246.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.